Market Highlights
The market for conjunctivitis drugs is facing stagnant growth in developed regions. Also, a number of patents which have expired such as Moxeza, Besivance, Vigamox, and Zymaxid have dampened the market growth. The market is further characterized by easy entry but high competition which has resulted into greater penetration by generics. The best strategy for firms is market development especially the Asian Pacific market which is poised to lead the growth of the global market in the near future. The market is further dampened by the better efficacy and broad spectrum of anti-bacterial drugs led by quinolones.
Quinolones especially Fluoroquinolones has a dominant market share for conjunctivitis. The research pipeline is somewhat weak with many other classes of antibiotics exhibiting greater toxicity. Thus, quinolones have immensely raised the acceptable bar for newer drugs.
Conjunctivitis Drugs Market size is expected to register 3.1% CAGR during the forecast period of 2019 to 2025 and will be valued at USD 1.18 Billion in 2025.
The market is chiefly driven by unmet needs in developing regions along with greater awareness and rising incomes in these regions. These reasons along with contagious nature of the disease along with rise of drug resistance also driving the market of other antibiotics which has greater toxicity such as macrolide class. Off label drug use is also one of the market drivers due to cheap generics and greater availability of these drugs.
Test the market data and market information presented in more than 60 market data tables and figures spread over 84 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “The Global Conjunctivitis Drugs Market Research Report - Forecast to 2022”.
Global Conjunctivitis Drugs market:
The global conjunctivitis drugs market has been evaluated to be growing and it is expected that it will touch high growth figures in future. The global conjunctivitis drugs market is expected to grow with CAGR of 3.1% in future. Market development and diversification into Asian Pacific market seems to have better strategy for the current situation.
Major participants of this market are: Akorn Pharmaceuticals, Alcon/ Novartis AG, Allergan Plc, Bausch & Lomb, Valeant Pharmaceuticals, Merck & Co. Inc., Actavis Plc., Pfizer Inc. and others.
Segmentation:
Global conjunctivitis drugs market has been segmented on the basis of conjunctivitis type which comprises of viral, bacterial, allergic and others types of conjunctivitis. On the basis of drug class; market is segmented into antibiotics (quinolones, aminoglycosides, macrolides and others), mast cell stabilizers, steroids and others. On the basis of route of administration; market is segmented into topical, oral and intra-vitreal. On the basis of end users; market is segmented into hospitals and self-administered.
http://marketresearchfuture.com/reports/conjunctivitis-drugs-market-2513